PSCI launches progressive position on the use of Horseshoe Crabs
A quarterly series of articles about responsible supply chain management from the PSCI.
Horseshoe Crabs are an ancient group of crab species that have been around for more than 400 million years. Their blood has the remarkable property of indicating certain types of endotoxins.
For this reason, it has been harvested by the medical and pharma industries to use as a test for these harmful compounds. Endotoxin testing using approved methods is a key demand of the regulators who authorise pharmaceutical development and manufacturing.
While this process does not require the death of the animal, there are still questions over possible animal welfare, biodiversity, and sustainability impacts from the collection of these materials from populations of wild crabs. Of the three affected species of Horseshoe Crabs across the USA and Asia, one Asian species is listed as endangered, with concerns over the other Asian species where data is deficient.
The connection between the Horseshoe Crab species and the pharmaceutical sector does highlight the importance of biodiversity for human health and acts an excellent example of interdependence between medicine and biodiversity. It also illustrates the complexity of biodiversity-related sourcing in a regulated industry.
However, it also emphasizes the need for the industry to take an active position, and so the Pharmaceutical Supply Chain Initiative (PSCI) has launched our progressive position paper on what we believe to be good practice for the use of Horseshoe Crab blood within the pharmaceutical industry.
“The PSCI is releasing this position paper to encourage our members to protect the endangered species, seek out alternatives to these materials, and to adopt an intentional approach to sourcing where it remains necessary. Our commitment is to work together now, to drive this transition towards a long-term sustainable position and to play our part in protecting these remarkable species.”
– A spokesperson for the PSCI.
Representing 75 of the world’s largest pharmaceutical companies, the PSCI will encourage its members to commit to no further collection from endangered species, minimising the use of these materials, and sharing information to understand the surrounding animal welfare and conservation questions.
While this paper is not a membership requirement for the PSCI, it does outline the organisation’s views on good practice as it continues its commitment to the protection of all endangered species. It is important the industry has a strategy for reducing its dependence on Horseshoe Crab-derived products, and the PSCI is committed to working with its members to facilitate their progress and report the position across the whole industry.
Read more via the button below.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance